August 1998
Volume 39, Issue 9
Free
Articles  |   August 1998
Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model.
Author Affiliations
  • K Tsubota
    Department of Ophthalmology, and the Oral Health Science Center, Tokyo Dental College, Chiba, Japan.
  • I Saito
    Department of Ophthalmology, and the Oral Health Science Center, Tokyo Dental College, Chiba, Japan.
  • N Ishimaru
    Department of Ophthalmology, and the Oral Health Science Center, Tokyo Dental College, Chiba, Japan.
  • Y Hayashi
    Department of Ophthalmology, and the Oral Health Science Center, Tokyo Dental College, Chiba, Japan.
Investigative Ophthalmology & Visual Science August 1998, Vol.39, 1551-1559. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K Tsubota, I Saito, N Ishimaru, Y Hayashi; Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model.. Invest. Ophthalmol. Vis. Sci. 1998;39(9):1551-1559.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

PURPOSE: A new animal model, the NFS/sld mutant mouse, was used for primary Sjögren's syndrome to investigate the efficacy of topical and systemic cyclosporin A (CyA) in preventing inflammation of the exocrine glands. METHODS: Cyclosporin A was applied topically (0.01% and 0.1%, three times a day) or administered orally (10 mg/kg and 100 mg/kg, once a day) to mice from 6 to 16 weeks of age, after which the mice were killed. RESULTS: Topical CyA reduced lacrimal gland and submandibular gland inflammation without causing pathologic changes in other organs. Flow cytometry showed that CD44 expression of CD4 T cells from the submandibular lymph nodes was downregulated, whereas that of Mel14+ was upregulated. Using a reverse transcription-polymerase chain reaction assay, we determined that topical CyA significantly decreased the expression of mRNA of IL-2 and T-cell receptor-constant beta-chain. CONCLUSIONS: Topical CyA may be clinically useful in reducing the lymphocyte infiltration of lacrimal glands associated with Sjögren's syndrome.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×